172 related articles for article (PubMed ID: 29436642)
21. The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer.
Krishnan AV; Swami S; Feldman D
Steroids; 2012 Sep; 77(11):1107-12. PubMed ID: 22801352
[TBL] [Abstract][Full Text] [Related]
22. Mycophenolic acid potentiates HER2-overexpressing SKBR3 breast cancer cell line to induce apoptosis: involvement of AKT/FOXO1 and JAK2/STAT3 pathways.
Aghazadeh S; Yazdanparast R
Apoptosis; 2016 Nov; 21(11):1302-1314. PubMed ID: 27651367
[TBL] [Abstract][Full Text] [Related]
23. Vitamin D receptor as a target for breast cancer therapy.
Murray A; Madden SF; Synnott NC; Klinger R; O'Connor D; O'Donovan N; Gallagher W; Crown J; Duffy MJ
Endocr Relat Cancer; 2017 Apr; 24(4):181-195. PubMed ID: 28213567
[TBL] [Abstract][Full Text] [Related]
24. Down-regulation of estrogen receptor-alpha and rearranged during transfection tyrosine kinase is associated with withaferin a-induced apoptosis in MCF-7 breast cancer cells.
Zhang X; Mukerji R; Samadi AK; Cohen MS
BMC Complement Altern Med; 2011 Oct; 11():84. PubMed ID: 21978374
[TBL] [Abstract][Full Text] [Related]
25. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
de Oliveira MB; Fook-Alves VL; Eugenio AIP; Fernando RC; Sanson LFG; de Carvalho MF; Braga WMT; Davies FE; Colleoni GWB
Cancer Lett; 2017 Sep; 403():206-215. PubMed ID: 28645562
[TBL] [Abstract][Full Text] [Related]
26. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells.
Mai Z; Blackburn GL; Zhou JR
Mol Carcinog; 2007 Jul; 46(7):534-42. PubMed ID: 17295235
[TBL] [Abstract][Full Text] [Related]
27. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer.
Naderi A; Chia KM; Liu J
Breast Cancer Res; 2011 Apr; 13(2):R36. PubMed ID: 21457548
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion.
Flanagan L; Packman K; Juba B; O'Neill S; Tenniswood M; Welsh J
J Steroid Biochem Mol Biol; 2003 Feb; 84(2-3):181-92. PubMed ID: 12711002
[TBL] [Abstract][Full Text] [Related]
29. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
Bogani C; Bartalucci N; Martinelli S; Tozzi L; Guglielmelli P; Bosi A; Vannucchi AM;
PLoS One; 2013; 8(1):e54826. PubMed ID: 23382981
[TBL] [Abstract][Full Text] [Related]
30. Ruxolitinib attenuates intimal hyperplasia via inhibiting JAK2/STAT3 signaling pathway activation induced by PDGF-BB in vascular smooth muscle cells.
Song HT; Cui Y; Zhang LL; Cao G; Li L; Li G; Jia XJ
Microvasc Res; 2020 Nov; 132():104060. PubMed ID: 32818511
[TBL] [Abstract][Full Text] [Related]
31. Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway.
Thoennissen NH; O'Kelly J; Lu D; Iwanski GB; La DT; Abbassi S; Leiter A; Karlan B; Mehta R; Koeffler HP
Oncogene; 2010 Jan; 29(2):285-96. PubMed ID: 19855437
[TBL] [Abstract][Full Text] [Related]
32. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
[TBL] [Abstract][Full Text] [Related]
33. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
[TBL] [Abstract][Full Text] [Related]
34. Pro-Apoptotic Activity of Ruxolitinib Alone and in Combination with Hydroxyurea, Busulphan, and PI3K/mTOR Inhibitors in JAK2-Positive Human Cell Lines.
Szymańska J; Smolewski P; Majchrzak A; Cebula-Obrzut B; Chojnowski K; Treliński J
Adv Clin Exp Med; 2015; 24(2):195-202. PubMed ID: 25931349
[TBL] [Abstract][Full Text] [Related]
35. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer.
Singh S; Shi Q; Bailey ST; Palczewski MJ; Pardee AB; Iglehart JD; Biswas DK
Mol Cancer Ther; 2007 Jul; 6(7):1973-82. PubMed ID: 17620428
[TBL] [Abstract][Full Text] [Related]
36. Transrepression of the estrogen receptor promoter by calcitriol in human breast cancer cells via two negative vitamin D response elements.
Swami S; Krishnan AV; Peng L; Lundqvist J; Feldman D
Endocr Relat Cancer; 2013 Aug; 20(4):565-77. PubMed ID: 23744764
[TBL] [Abstract][Full Text] [Related]
37. Co-targeting ER and HER family receptors induces apoptosis in HER2-normal or overexpressing breast cancer models.
Chakraborty AK; Mehra R; Digiovanna MP
Anticancer Res; 2015 Mar; 35(3):1243-50. PubMed ID: 25750271
[TBL] [Abstract][Full Text] [Related]
38. A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines.
Puig T; Aguilar H; Cufí S; Oliveras G; Turrado C; Ortega-Gutiérrez S; Benhamú B; López-Rodríguez ML; Urruticoechea A; Colomer R
Breast Cancer Res; 2011; 13(6):R131. PubMed ID: 22177475
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
40. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]